日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer

出版商更正:APOBEC3 突变驱动乳腺癌治疗耐药性

Gupta, Avantika; Gazzo, Andrea; Selenica, Pier; Safonov, Anton; Pareja, Fresia; da Silva, Edaise M; Brown, David N; Shao, Hong; Zhu, Yingjie; Patel, Juber; Blanco-Heredia, Juan; Stefanovska, Bojana; Carpenter, Michael A; Chen, Yanjun; Vegas, Isabella; Pei, Xin; Frosina, Denise; Jungbluth, Achim A; Ladanyi, Marc; Curigliano, Giuseppe; Weigelt, Britta; Riaz, Nadeem; Powell, Simon N; Razavi, Pedram; Harris, Reuben S; Reis-Filho, Jorge S; Marra, Antonio; Chandarlapaty, Sarat

Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy

对接受新辅助化疗的II-III期乳腺癌患者循环肿瘤DNA进行监测

Cabel, Luc; An, Julia Ah-Reum; Kim, Hong-Kyu; Kim, Jisun; Smith, Christopher Gareth; Chevalier, Amber; Erazo, Tatiana; Moiso, Enrico; Ferraro, Emanuela; Safonov, Anton; Nelson, Konner; Szuhany, Kathleen; Drago, Joshua Z; Norton, Larry; Xu, Amy; Khan, Atif J; Li, Bob T; Robson, Mark E; Chandarlapaty, Sarat; Plitas, George; Razavi, Pedram

Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer

通过循环肿瘤DNA分析追踪乳腺癌新辅助全身治疗的反应

Marra, Antonio; Kim, Sarah H; Pareja, Fresia; Basili, Thais; Solit, David B; Chandarlapaty, Sarat; Plitas, George; Reis-Filho, Jorge S; Weigelt, Britta; King, Tari A; Brown, David N

Poly(I:C) and R848 adjuvants elicit sizeable humoral immunity to liver stage malaria antigens

Poly(I:C)和R848佐剂可诱导针对肝期疟疾抗原的显著体液免疫反应。

Tandel, Nikunj; Thakkar, Mansi; Ahuja, Mansi; Shah, Jagrut; Trivedi, Devangkumar D; Pied, Sylviane; Singh, Agam P; Prajapati, Chirag; Tyagi, Rajeev K; Dalai, Sarat K

Pallidothalamic Tractotomy after Pallidotomy for Medication-Refractory Dystonia: Preliminary Short-Term Results from a Case Series of Five Patients

苍白球切开术后行苍白球丘脑束切开术治疗药物难治性肌张力障碍:5例患者病例系列的初步短期结果

Garg, Divyani; Das, Animesh; Adhya, Arnab; Radhakrishnan, Divya M; Rajan, Roopa; Elavarasi, Arunmozhimaran; Thoibisana, Ashem; Garg, Ajay; Srivastava, Achal Kumar; Singh, Manmohan; Chandra, P Sarat; Garg, Kanwaljeet

CSF tap test parameters and Short-Term outcomes in operated and non-operated patients with idiopathic normal pressure Hydrocephalus: A cohort study

脑脊液穿刺试验参数及特发性正常压力脑积水手术组和非手术组患者的短期预后:一项队列研究

Poudel, Sagar; Dash, Deepa; Wagle Shukla, Aparna; Garg, Ajay; Upadhyay, Ashish Dutt; Wig, Naveet; Rajan, Roopa; Das, Animesh; Mr, Divya; Tripathi, Manjari; Srivastava, Achal K; Kale, S S; Chandra, Poodipedi Sarat; Suri, Ashish; Pal, Pramod K; Kumar, Hrishikesh; Saggu, Sakoon; Vibha, Deepti; Singh, Rajesh Kumar; Parihar, Jasmine; Jadon, Ranveer Singh; Meena, Ved Prakash; Prakash, Bindu; Elavarasi, Arunmozhimaran

Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer.

对肿瘤抑制基因双等位基因失活的泛癌分析表明,KEAP1 合子性是肺癌的预测性生物标志物

Zucker Mark, Perry Maria A, Gould Samuel I, Elkrief Arielle, Safonov Anton, Thummalapalli Rohit, Mehine Miika, Chakravarty Debyani, Brannon A Rose, Ladanyi Marc, Razavi Pedram, Donoghue Mark T A, Murciano-Goroff Yonina R, Grigoriadis Kristiana, McGranahan Nicholas, Jamal-Hanjani Mariam, Swanton Charles, Chen Yuan, Shen Ronglai, Chandarlapaty Sarat, Solit David B, Schultz Nikolaus, Berger Michael F, Chang Jason, Schoenfeld Adam J, Sánchez-Rivera Francisco J, Reznik Ed, Bandlamudi Chaitanya

Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters

Kmt2c 或 Kmt2d 的缺失会使尿路上皮细胞更容易发生肿瘤,并将 KMT2A-menin 重新分布到二价启动子。

Naitao Wang # ,Mohini R Pachai # ,Dan Li # ,Cindy J Lee ,Sarah Warda ,Makhzuna N Khudoynazarova ,Woo Hyun Cho ,Guojia Xie ,Sagar R Shah ,Li Yao ,Cheng Qian ,Elissa W P Wong ,Juan Yan ,Fanny V Tomas ,Wenhuo Hu ,Fengshen Kuo ,Sizhi P Gao ,Jiaqian Luo ,Alison E Smith ,Ming Han ,Dong Gao ,Kai Ge ,Haiyuan Yu ,Sarat Chandarlapaty ,Gopakumar V Iyer ,Jonathan E Rosenberg ,David B Solit ,Hikmat A Al-Ahmadie ,Ping Chi ,Yu Chen

APOBEC3 mutagenesis drives therapy resistance in breast cancer

APOBEC3突变驱动乳腺癌的治疗耐药性

Avantika Gupta #,Andrea Gazzo #,Pier Selenica,Anton Safonov,Fresia Pareja,Edaise M da Silva,David N Brown,Hong Shao,Yingjie Zhu,Juber Patel,Juan Blanco-Heredia,Bojana Stefanovska,Michael A Carpenter,Yanjun Chen,Isabella Vegas,Xin Pei,Denise Frosina,Achim A Jungbluth,Marc Ladanyi,Giuseppe Curigliano,Britta Weigelt,Nadeem Riaz,Simon N Powell,Pedram Razavi,Reuben S Harris,Jorge S Reis-Filho,Antonio Marra,Sarat Chandarlapaty

Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding

曲妥珠单抗德鲁替康(T-DXd)耐药性通过HER2表达和结合的丧失而产生

Wanyi Chen ,Avantika Gupta ,Nicholas Mai ,Sharanya Nag ,Joshua S Lau ,Sukrit Singh ,John D Chodera ,Bo Liu ,Elisa de Stanchina ,Fresia Pareja ,Atif Ali Hashmi ,Miriam M Lieberman ,Shanu Modi ,Jacqueline Bromberg ,Pedram Razavi ,Joshua Z Drago ,Sarat Chandarlapaty